Immune checkpoint blockade, which blocks inhibitory signals of T cell activation, has shown
tremendous success in treating cancer, although success still remains limited to a fraction of …

Whole-genome sequencing has brought the cancer genomics community into new territory.
Thanks to the sheer power provided by the thousands of mutations present in each patient's …

Despite neoadjuvant/conversion chemotherapy, the prognosis of cT4a/bN+ gastric cancer is
poor. Immune checkpoint inhibitors (ICIs) and antiangiogenic agents have shown activity in …

Metastatic progression is the main cause of death in cancer patients, whereas the
underlying genomic mechanisms driving metastasis remain largely unknown. Here, we …

Only a fraction of patients with cancer respond to immune checkpoint blockade (ICB)
treatment, but current decision-making procedures have limited accuracy. In this study, we …

There is a continuing debate about the proportion of cancer patients that benefit from
precision oncology, attributable in part to conflicting views as to which molecular alterations …

Following initial successes in melanoma treatment, immunotherapy has rapidly become
established as a major treatment modality for multiple types of solid cancers, including a …

Microsatellite unstable (MSI) colorectal cancers (CRCs) are due to DNA mismatch repair
(MMR) deficiency and occurs in15% of non-metastatic diseases and 5% in the metastatic …

Cancers that appear morphologically similar often have dramatically different clinical
features, respond variably to therapy and have a range of outcomes. Compelling evidence …

The incidence of rectal cancer is increasing in patients younger than 50 years. Locally
advanced rectal cancer is still treated with neoadjuvant radiation, chemotherapy and …